Cholinergic stimulation of drinking from the lateral hypothalamus: indications for M2 muscarinic receptor mediation.
Available evidence suggests that muscarinic receptor binding sites may exist in at least two heterogenous subclasses (M1 and M2), distinguished by their affinity for the antagonist pirenzepine. In order to evaluate the role of these receptors in comsummatory behaviour a series of conventional and putatively receptor selective drugs were tested for their effects on water consumption following injection (0.5 microliter/30 sec) into the perifornical hypothalamic area of non-deprived rats. Of the conventional agonists tested, carbachol and oxotremorine were approximately equipotent and arecoline was about 16 X weaker. Of the putative M1 agonists tested, pilocarpine was about 50 X weaker than carbachol and the remainder (MCNA343, AHR602, AH6405) were inactive. Inhibition of carbachol (1 microgram) induced drinking was subsequently measured. The most potent inhibition was found using scopolamine, a non selective antagonist. 4-DAMP was approximately 7 X weaker than scopolamine, but was more potent than the putative M1 antagonists pirenzepine, telenzepine or dicyclomine. In a separate series of experiments the affinity of these drugs for [3H]pirenzepine forebrain receptors (M1) and [3H]QNB brainstem receptors (M2) was determined to confirm their receptor binding selectivity. No systematic relationship was found between agonist potency and M1 or M2 affinities. M2 receptor involvement was indicated by the antagonist data which show a close relationship between rank potency order and M2 receptor affinity. An important role for M1 receptors is excluded by the absence of a clear relationship between potency order and M1 affinity. The data therefore suggest an important role for M2 receptors in mediating drinking stimulated by muscarinic receptor activation.
D000818:Animals; D004327:Drinking Behavior / Q000187:drug effects / Q000502:physiology*; D007031:Hypothalamus / Q000187:drug effects / Q000502:physiology*; D008297:Male; D010276:Parasympatholytics / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology; D051381:Rats; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology*
D010276:Parasympatholytics; D010277:Parasympathomimetics; D011976:Receptors, Muscarinic